Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Nicolas Guerard"'
Autor:
Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Melissa Liew, Margarita Gekkieva, Markus Hinder
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 2, Pp n/a-n/a (2022)
Abstract This was a prospective, single‐dose, single‐arm, open‐label, non‐randomized, multicenter clinical study to determine cardiovascular safety after a single brolucizumab 6 mg intravitreal injection in neovascular age‐related macular d
Externí odkaz:
https://doaj.org/article/627ef13d9aab4d2aa272395adb6378ee
Autor:
David M. Brown, Andrés Emanuelli, Francesco Bandello, Jose Juan Escobar Barranco, João Figueira, Eric Souied, Sebastian Wolf, Vishali Gupta, Nor Fariza Ngah, Gerald Liew, Raman Tuli, Ramin Tadayoni, Dilsher Dhoot, Lixin Wang, Emmanuel Bouillaud, Ying Wang, Lidija Kovacic, Nicolas Guerard, Justus G. Garweg
Publikováno v:
Brown, David M; Emanuelli, Andrés; Bandello, Francesco; Barranco, Jose Juan Escobar; Figueira, João; Souied, Eric; Wolf, Sebastian; Gupta, Vishali; Ngah, Nor Fariza; Liew, Gerald; Tuli, Raman; Tadayoni, Ramin; Dhoot, Dilsher; Wang, Lixin; Bouillaud, Emmanuel; Wang, Ying; Kovacic, Lidija; Guerard, Nicolas; Garweg, Justus (2022). KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. American journal of ophthalmology, 238, pp. 157-172. 10.1016/j.ajo.2022.01.004
PURPOSE To compare the efficacy and safety of brolucizumab with aflibercept in patients with diabetic macular edema (DME). DESIGN Double-masked, 100-week, multicenter, active-controlled, randomized trials. METHODS Subjects were randomized 1:1:1 to br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d1b6ad06714782431b29f8ea0c57d2f
https://doi.org/10.1016/j.ajo.2022.01.004
https://doi.org/10.1016/j.ajo.2022.01.004